MA31158B1 - Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes - Google Patents

Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Info

Publication number
MA31158B1
MA31158B1 MA32128A MA32128A MA31158B1 MA 31158 B1 MA31158 B1 MA 31158B1 MA 32128 A MA32128 A MA 32128A MA 32128 A MA32128 A MA 32128A MA 31158 B1 MA31158 B1 MA 31158B1
Authority
MA
Morocco
Prior art keywords
modifiers
tricyclic compounds
glucocorticoid receptors
compounds
salts
Prior art date
Application number
MA32128A
Other languages
Arabic (ar)
English (en)
Inventor
Hengmiao Cheng
Xiao Hu
Kevin Dewayne Jerome
Mark Gerard Obukowicz
Lisa Olson
Paul Vincent Rucker
Ronald Keith Webber
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/000249 external-priority patent/WO2008093236A1/fr
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31158B1 publication Critical patent/MA31158B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des composés de formule (i), ou leurs sels, qui sont des modulateurs du récepteur des glucocorticoïdes. Les composés et les sels de l'invention sont utiles dans le traitement d'affections médiées par l'activité des récepteurs des glucocorticoïdes.
MA32128A 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes MA31158B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000249 WO2008093236A1 (fr) 2007-02-02 2008-01-28 Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Publications (1)

Publication Number Publication Date
MA31158B1 true MA31158B1 (fr) 2010-02-01

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Country Status (42)

Country Link
US (7) US7598231B2 (fr)
EP (1) EP2114970B1 (fr)
JP (1) JP4599462B2 (fr)
KR (2) KR101107949B1 (fr)
CN (2) CN101616925B (fr)
AP (1) AP2455A (fr)
AR (2) AR065134A1 (fr)
AT (1) ATE518872T1 (fr)
AU (1) AU2008211613B2 (fr)
BR (1) BRPI0808634A2 (fr)
CA (1) CA2676670C (fr)
CL (2) CL2008000330A1 (fr)
CO (2) CO6220937A2 (fr)
CR (2) CR10949A (fr)
CU (2) CU23848B1 (fr)
CY (2) CY1110962T1 (fr)
DK (1) DK2114970T3 (fr)
DO (1) DOP2009000190A (fr)
EA (1) EA016494B1 (fr)
EC (2) ECSP099553A (fr)
ES (2) ES2368286T3 (fr)
GE (2) GEP20125404B (fr)
GT (2) GT200900209A (fr)
HN (2) HN2008000178A (fr)
HR (1) HRP20110702T1 (fr)
IL (1) IL199972A (fr)
MA (2) MA31117B1 (fr)
MX (1) MX2009008284A (fr)
MY (3) MY146087A (fr)
NI (2) NI200900148A (fr)
NZ (1) NZ578638A (fr)
PE (2) PE20081736A1 (fr)
PL (1) PL2114970T3 (fr)
PT (2) PT2114970E (fr)
RS (2) RS51970B (fr)
SI (1) SI2114970T1 (fr)
SV (2) SV2009003346A (fr)
TN (1) TN2009000324A1 (fr)
TW (2) TWI373466B (fr)
UA (2) UA94639C2 (fr)
WO (1) WO2008093227A1 (fr)
ZA (2) ZA200906064B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
WO2008093227A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes
ES2527137T3 (es) * 2008-07-28 2015-01-21 Pfizer Inc. Compuestos de fenantrenona, composiciones y procedimientos
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EP2569307A2 (fr) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Dérivés d'acide lipoïque et de nitroxide et leurs utilisations
MX2013002186A (es) * 2010-08-27 2013-06-28 Corcept Therapeutics Inc Moduladores de azadecalina de piridil-amina fusionada.
WO2012125797A1 (fr) * 2011-03-15 2012-09-20 Abbott Laboratories Modulateurs des récepteurs hormonaux nucléaires
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) * 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
AU2015258904A1 (en) 2014-05-16 2016-11-17 Liqwd, Inc. Keratin treatment formulations and methods
EP3848028B9 (fr) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Méthodes de traitement de troubles oculaires
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
US10722513B2 (en) * 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
EP3877382B1 (fr) 2018-11-07 2026-03-18 Tianli Biotech Pty Ltd Nouveaux composés pour le traitement de maladies respiratoires

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
HK1042889B (zh) 1999-04-30 2006-12-29 辉瑞产品公司 糖皮质激素受体调制剂
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
JP2002193911A (ja) * 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
GB2387468B (en) * 2000-11-20 2005-01-19 Seagate Technology Llc RF ID Tag attachment to a disc drive
MXPA03011935A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
CN1556708A (zh) 2001-08-31 2004-12-22 �Ƹ��� 抑制成年唐氏综合症患者认知退化的方法
EP1432684B1 (fr) 2001-09-27 2009-03-25 Université de Liège Derives de sulfonamide pyridinique, procede de fabrication et d'utilisation
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
WO2003063833A1 (fr) 2002-02-01 2003-08-07 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
JP2005535664A (ja) 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
ES2518940T3 (es) * 2002-07-08 2014-11-06 Pfizer Products Inc. Moduladores del receptor de glucocorticoides
EP1581234A4 (fr) 2002-11-05 2007-09-12 Corcept Therapeutics Inc Procédés pour traiter la migraine
US20040229855A1 (en) 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
US7592177B2 (en) * 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2004289532A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
AU2007248059A1 (en) 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2008093227A1 (fr) * 2007-02-02 2008-08-07 Pfizer Products Inc. Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes
AU2008211622B2 (en) * 2007-02-02 2012-04-19 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators

Also Published As

Publication number Publication date
CN101616925A (zh) 2009-12-30
NI200900148A (es) 2010-02-15
CA2676670A1 (fr) 2008-08-07
TN2009000324A1 (fr) 2010-12-31
TW200846325A (en) 2008-12-01
SV2009003346A (es) 2010-04-13
TWI373466B (en) 2012-10-01
AP2009004942A0 (en) 2009-08-31
CO6220937A2 (es) 2010-11-19
WO2008093227A1 (fr) 2008-08-07
ES2353822T3 (es) 2011-03-07
EA016494B1 (ru) 2012-05-30
CR10948A (es) 2009-08-07
BRPI0808634A2 (pt) 2014-08-05
US20080312294A1 (en) 2008-12-18
NI200900149A (es) 2010-02-15
MX2009008284A (es) 2009-08-12
US20120088802A9 (en) 2012-04-12
EA200970666A1 (ru) 2010-02-26
JP4599462B2 (ja) 2010-12-15
PL2114970T3 (pl) 2011-11-30
GT200900210A (es) 2010-04-05
US20140316139A1 (en) 2014-10-23
ZA200906064B (en) 2010-05-26
CL2008000330A1 (es) 2008-08-08
KR101114682B1 (ko) 2012-03-14
JP2010517990A (ja) 2010-05-27
CY1111758T1 (el) 2015-10-07
CY1110962T1 (el) 2015-06-11
AP2455A (en) 2012-08-31
HRP20110702T1 (hr) 2011-10-31
HN2008000178A (es) 2011-02-25
GT200900209A (es) 2010-07-22
CR10949A (es) 2009-08-07
RS51646B (sr) 2011-10-31
IL199972A0 (en) 2010-04-15
MY148780A (en) 2013-05-31
US7547714B2 (en) 2009-06-16
ES2368286T3 (es) 2011-11-16
US20120095062A1 (en) 2012-04-19
SV2009003349A (es) 2010-04-13
AU2008211613A1 (en) 2008-08-07
US20090281148A1 (en) 2009-11-12
CL2008000329A1 (es) 2008-08-08
AR065135A1 (es) 2009-05-20
EP2114970A1 (fr) 2009-11-11
GEP20125404B (en) 2012-02-27
US7598231B2 (en) 2009-10-06
ATE518872T1 (de) 2011-08-15
AU2008211613B2 (en) 2013-05-23
US20080188443A1 (en) 2008-08-07
RS51970B (sr) 2012-02-29
KR20090107080A (ko) 2009-10-12
US20140142316A1 (en) 2014-05-22
CA2676670C (fr) 2012-03-13
CU23848B1 (es) 2012-10-15
CN101616896B (zh) 2012-07-04
MY146087A (en) 2012-06-29
KR20090108115A (ko) 2009-10-14
CU20090132A7 (es) 2011-10-14
ECSP099552A (es) 2009-08-28
ECSP099553A (es) 2009-08-28
IL199972A (en) 2013-09-30
PT2114970E (pt) 2011-09-22
NZ578638A (en) 2010-12-24
TW200838514A (en) 2008-10-01
MY153057A (en) 2014-12-31
PT2114888E (pt) 2011-01-04
MA31117B1 (fr) 2010-01-04
CU23824A3 (es) 2011-10-31
HN2008000179A (es) 2010-06-09
CN101616925B (zh) 2012-05-23
DK2114970T3 (da) 2011-09-19
US8901310B2 (en) 2014-12-02
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
UA95332C2 (uk) 2011-07-25
UA94639C2 (ru) 2011-05-25
GEP20125426B (en) 2012-03-26
SI2114970T1 (sl) 2011-11-30
ZA200906060B (en) 2010-05-26
DOP2009000190A (es) 2009-08-31
CN101616896A (zh) 2009-12-30
CO6190603A2 (es) 2010-08-19
TWI347842B (en) 2011-09-01
AR065134A1 (es) 2009-05-20
US8445520B2 (en) 2013-05-21
EP2114970B1 (fr) 2011-08-03
HK1135108A1 (en) 2010-05-28
KR101107949B1 (ko) 2012-02-08
PE20090113A1 (es) 2009-02-13
US20100286214A1 (en) 2010-11-11
CU20090133A7 (es) 2011-10-31
US7786097B2 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
DE602007008524D1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
EP2004177A4 (fr) Composes de nitrofurane utilises dans le traitement du cancer et de l'angiogenese
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EA201290532A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
TNSN08275A1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines